Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis

References

• Benoit-Biancamano MO, Caron P, Levesque E, et al. (2007). Sensitive high-performance liquid chromatography-tandem mass spectrometry method for quantitative analysis of mycophenolic acid and its glucuronide metabolites in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 858:159–67
   PubMed Web of Science ®Google Scholar
• Bullingham RE, Nicholls AJ, Kamm BR. (1998). Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429–55
   PubMed Web of Science ®Google Scholar
• Christie JD, Edwards LB, Kucheryavaya AY, et al. (2011). The registry of the international society for heart and lung transplantation: twenty-eighth adult lung and heart-lung transplant report–2011. J Heart Lung Transplant 30:1104–22
   PubMed Web of Science ®Google Scholar
• Colom H, Lloberas N, Andreu F, et al. (2014). Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney Int 85:1434–43
   PubMed Web of Science ®Google Scholar
• Cremers S, Schoemaker R, Scholten E, et al. (2005). Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol 60:249–56
   PubMed Web of Science ®Google Scholar
• de Winter BC, Monchaud C, Premaud A, et al. (2012). Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients. Clin Pharmacokinet 51:29–39
   PubMed Web of Science ®Google Scholar
• Debray D, Rainteau D, Barbu V, et al. (2012). Defects in gallbladder emptying and bile acid homeostasis in mice with cystic fibrosis transmembrane conductance regulator deficiencies. Gastroenterology. 142:1581–91 e6
   PubMed Web of Science ®Google Scholar
• Fujiyama N, Miura M, Kato S, et al. (2010). Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab Dispos 38:2210–17
   PubMed Web of Science ®Google Scholar
• Gerbase MW, Fathi M, Spiliopoulos A, et al. (2003). Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis. J Heart Lung Transplant 22:587–90
   PubMed Web of Science ®Google Scholar
• Johnson HJ, Swan SK, Heim-Duthoy KL, et al. (1998). The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther 63:512–18
   PubMed Web of Science ®Google Scholar
• Ling J, Shi J, Jiang Q, Jiao Z. (2014). Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil. Eur J Clin Pharmacol 71:95–106
   PubMed Web of Science ®Google Scholar
• Pittman FE, Denning CR, Barker HG. (1964). Albumin metabolism in cystic fibrosis. Am J Dis Child 108:360–5
   PubMedGoogle Scholar
• Quattrucci S, Rolla M, Cimino G, et al. (2005). Lung transplantation for cystic fibrosis: 6-year follow-up. J Cyst Fibros 4:107–14
   PubMedGoogle Scholar
• Boucher RC, (2012). Chapter 259. Cystic fibrosis. In: Longo DL, Fauci AS, Kasper DL eds. Harrison's principles of internal medicine. 18th ed.New York, NY: McGraw-Hill Inc. 1194–7
   Google Scholar
• Rey E, Treluyer JM, Pons G. (1998). Drug disposition in cystic fibrosis. Clin Pharmacokinet 35:313–29
   PubMed Web of Science ®Google Scholar
• Sam WJ, Akhlaghi F, Rosenbaum SE. (2009). Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients. J Clin Pharmacol 49:185–95
   PubMed Web of Science ®Google Scholar
• Savic RM, Karlsson MO. (2009). Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11:558–69
   PubMed Web of Science ®Google Scholar
• Shum B, Duffull SB, Taylor PJ, Tett SE. (2003). Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol 56:188–97
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. (2007). Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46:13–58
   PubMed Web of Science ®Google Scholar
• Stead RJ, Houlder S, Agnew J, et al. (1988). Vitamin D and parathyroid hormone and bone mineralisation in adults with cystic fibrosis. Thorax 43:190–4
   PubMed Web of Science ®Google Scholar
• Strober W, Peter G, Schwartz RH. (1969). Albumin metabolism in cystic fibrosis. Pediatrics 43:416–26
   PubMed Web of Science ®Google Scholar
• Stuckey L, Clark Ojo T, Park JM, et al. (2014). Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. Ther Drug Monit 36:148–51
   PubMed Web of Science ®Google Scholar
• Sugioka N, Sasaki T, Kokuhu T, et al. (2006). Clinical pharmacokinetics of mycophenolate mofetil in Japanese renal transplant recipients: a retrospective cohort study in a single center. Biol Pharm Bull 29:2099–105
   PubMed Web of Science ®Google Scholar
• Ting LS, Partovi N, Levy RD, et al. (2006). Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients. Ann Pharmacother 40:1509–16
   PubMed Web of Science ®Google Scholar
• van Hest RM, Mathot RA, Pescovitz MD, et al. (2006). Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 17:871–80
   PubMed Web of Science ®Google Scholar
• van Hest RM, van Gelder T, Vulto AG, Mathot RA. (2005). Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 44:1083–96
   PubMed Web of Science ®Google Scholar
• Wang X, Kay A, Anak O, et al. (2013). Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib. J Clin Pharmacol 53:14–20
   PubMed Web of Science ®Google Scholar
• Wang XX, Feng MR, Nguyen H, et al. (2015). Population pharmacokinetics of mycophenolic acid in lung transplant recipients with and without cystic fibrosis. Eur J Clin Pharmacol 71:673–9
   PubMed Web of Science ®Google Scholar
• Woillard JB, Rerolle JP, Picard N, et al. (2010). Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. Br J Clin Pharmacol 69:675–83
   PubMed Web of Science ®Google Scholar